Episode 261: ctDNA in Urothelial Studies Part 2

By Matthew D. Galsky, MD - Last Updated: September 7, 2023

Matt Galsky, MD, continues his discussion on the use of ctDNA in bladder cancer, and covers topics such as candidate versus panel approaches and the advantages and disadvantages of both.
Dr. Galsky is an oncologist and director of GU medical oncology at The Tisch Cancer Institute, Mount Sinai.

Post Tags:Uromigos-Bladder Cancer